LPL Financial LLC Purchases 98,004 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

LPL Financial LLC increased its position in MiMedx Group, Inc. (NASDAQ:MDXG) by 213.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 143,845 shares of the company’s stock after acquiring an additional 98,004 shares during the period. LPL Financial LLC owned about 0.10% of MiMedx Group worth $1,384,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of MDXG. IMG Wealth Management Inc. purchased a new position in MiMedx Group in the fourth quarter worth about $28,000. Van ECK Associates Corp purchased a new position in shares of MiMedx Group in the fourth quarter worth approximately $40,000. SkyView Investment Advisors LLC grew its position in MiMedx Group by 30.0% during the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company’s stock valued at $77,000 after buying an additional 3,000 shares during the period. AlphaQuest LLC purchased a new stake in MiMedx Group during the fourth quarter valued at approximately $88,000. Finally, Savant Capital LLC bought a new position in MiMedx Group in the fourth quarter worth approximately $100,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Stock Up 0.7 %

Shares of MDXG stock opened at $6.68 on Friday. The company has a market capitalization of $983.67 million, a price-to-earnings ratio of 12.14 and a beta of 1.74. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The company’s fifty day moving average price is $7.72 and its 200-day moving average price is $8.00. MiMedx Group, Inc. has a one year low of $5.47 and a one year high of $10.14.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, meeting the consensus estimate of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The business had revenue of $92.91 million for the quarter, compared to the consensus estimate of $89.42 million. Sell-side analysts expect that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MDXG has been the subject of a number of recent research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 price objective on shares of MiMedx Group in a research report on Thursday, February 27th. StockNews.com lowered MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Wednesday.

Insiders Place Their Bets

In related news, insider Kimberly Maersk-Moller sold 4,106 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $32,396.34. Following the sale, the insider now directly owns 310,836 shares in the company, valued at approximately $2,452,496.04. The trade was a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO William Frank Iv Hulse sold 54,596 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $430,762.44. Following the transaction, the chief accounting officer now owns 440,178 shares of the company’s stock, valued at $3,473,004.42. This represents a 11.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 144,018 shares of company stock worth $1,130,312 in the last three months. 1.30% of the stock is owned by company insiders.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.